Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 11/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | XIAP | P98170 | 8/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23714232 | 1.00 | BIRC2 (0.46) | BIRC2PIK3CDXIAPCHRM1HRH3 | |
| SCHEMBL27320502 | 0.84 | BIRC2 (0.47) | BIRC2XIAPMLNRCYP3A4 | |
| SCHEMBL8733534 | 0.84 | BIRC2 (0.44) | BIRC2XIAPCHRM1 | |
| SCHEMBL3109196 | 0.82 | BIRC2 (0.42) | BIRC2XIAPCHRM1MLNR | |
| SCHEMBL17906594 | 0.82 | BIRC2 (0.49) | BIRC2XIAPCHRM1MLNRCYP3A4 | |
| SCHEMBL27341041 | 0.82 | BIRC2 (0.49) | BIRC2XIAPCHRM1MLNRCYP3A4 | |
| SCHEMBL13766678 | 0.82 | BIRC2 (0.45) | BIRC2XIAPCHRM1 | |
| SCHEMBL10730345 | 0.82 | BIRC2 (0.45) | BIRC2XIAPCHRM1 | |
| SCHEMBL3098422 | 0.81 | BIRC2 (0.41) | BIRC2XIAP | |
| Hydrochloric Acid SCHEMBL27151220 | 0.80 | BIRC2 (0.47) | BIRC2XIAPCHRM1MLNRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| EP-2204394-B1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | TOSOH CORP (JP) | 2017-07-12 | — | — | EP | disclosed |
| US-8980965-B2 | Method for producing polyester type flexible polyurethane foam, and catalyst composition to be used therefor | TOSOH CORPORATION (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | TOSOH CORPORATION (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2204394-A1 | PROCESS FOR PRODUCTION OF POLYESTER-CONTAINING FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION FOR USE IN THE PROCESS | Tosoh Corporation (JP) | 2010-07-07 | — | — | EP | disclosed |
| EP-0049683-A2 | Imidazo-rifamycines, process for their preparation, pharmaceutical preparations containing them and their use | CIBA-GEIGY AG (CH) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | BIRC2 3369/4885PIK3CD 3833/4885XIAP 3039/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | BIRC2 3350/4885PIK3CD 336/4885XIAP 1046/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | BIRC2 3369/4885PIK3CD 3833/4885XIAP 3039/4885 |
| US-20100256249-A1 | METHOD FOR PRODUCING POLYESTER TYPE FLEXIBLE POLYURETHANE FOAM, AND CATALYST COMPOSITION TO BE USED THEREFOR | OR51E2, CYP4F11, FFAR3 | BIRC2 2156/4885PIK3CD 2861/4885XIAP 4553/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | BIRC2 3878/4885PIK3CD 4021/4885XIAP 3241/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | BIRC2 3098/4885PIK3CD 288/4885XIAP 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.